19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
U.S. Teachers Often Faced Harassment, Violence During Pandemic: PollOmicron Wave Had 5 Times as Many Small Kids Hospitalized Compared to DeltaSuicide Rate Is Spiking Upwards in Preadolescent ChildrenAHA News: Bystander CPR on Kids Differs by Race and EthnicityNew Malaria Treatment Gets First Approval for Use in ChildrenMental Health of America's Children Only Getting WorseTalking to Your Kids About the War in UkraineOdds for Mental Illness Rise in Kids After ConcussionPfizer Begins Trial of COVID Drug Paxlovid in Kids 6 to 17Pfizer Vaccine Much Less Potent in Kids Aged 5-11COVID Has Robbed 5.2 Million Children Worldwide of Parent, CaregiverNew Drug May Help Curb COVID-Linked Inflammatory Disorder in KidsPoll Finds Most Parents Would Use CBD to Treat a Child — Is That Wise?Does Your Child Have Asthma? Look for the SignsResearch May Help Focus Treatment for Kids With Cystic FibrosisSleepless Children Often Become Sleepless Adults: StudyA Healthy Mouth Could Be a Lifesaver for Kids With Heart ConditionsSeasonal Flu Shots Give Kids Broader Protection Against New StrainsU.S. Kids Still Dying From Toppling TVs, FurnitureKids With COVID-Linked MIS-C Have Long-Term SymptomsAHA News: Amid a National Mental Health Crisis For Kids, Here's How Parents Can HelpParents: What You Need to Know About Kids & COVID-19Getting Active Soon After Concussion May Aid Kids' RecoveryPfizer Asks FDA to Approve Its Vaccine for Youngest KidsThe 'Oreo Test' and Other Ways to Help Kids' Oral HealthPfizer Will Ask FDA to Approve Its COVID Vaccine for Kids Under 5Getting Your School-Age Child Into a Healthy Sleep RoutineGenes Could Help Drive Febrile Convulsions in KidsMore Than 1 Million U.S. Kids Diagnosed With COVID in Single WeekPandemic Especially Tough on Kids With ADHDBrain Implant for Adults With Epilepsy Can Help Kids, TooCOVID Can Affect Brains of Hospitalized KidsMany Kids Aren't Wearing Helmets While Sledding, Poll FindsMany Marijuana Vendors Aim Advertising at Kids: StudyHeart Function Rebounds for Kids With COVID-Linked MIS-CWhich Kids Are Most Vulnerable to Severe COVID-19?At-Home COVID Tests Accurate for Ki​ds: StudyCDC Study Shows Power of Flu Vaccine for KidsCOVID Hospitalizations Rising in Kids Too Young for VaccineNearly 600,000 U.S. Kids Had COVID Last WeekWhite House to Give Schools 10 Million Free COVID Tests Every MonthKids' Behavior Worsened With Remote Learning: StudyLater School Start Times Boost Parents' Health, TooUrban Air Pollution Drives Millions of Cases of Asthma in KidsCDC Backs Boosters for High-Risk Kids Aged 5-11, Shorter Time Between ShotsA Better Way to Correct Severe Scoliosis in Kids?Getting Your Child Their Vaccine?  Some Tips on Easing Needle FearsU.S. Hospitals Seeing Record Numbers of Young COVID PatientsSevere Illness in Children Brings Hardship for FamiliesReal-World Data Confirms Pfizer Vaccine Safe for Kids Ages 5-11
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

Pfizer Asks FDA to Approve Its Vaccine for Youngest Kids

HealthDay News
by By Robin Foster HealthDay Reporter
Updated: Feb 2nd 2022

new article illustration

WEDNESDAY, Feb. 2, 2022 (HealthDay News) -- Pfizer Inc. announced Tuesday that it has asked the U.S. Food and Drug Administration to authorize its two-dose COVID vaccine for emergency use in children under 5 while it continues to research the power of a third shot in these youngest Americans.

If the FDA grants the request, the two-shot regimen would become the first approved for use in children this young; older children are already eligible for the vaccine. In December, Pfizer suffered a setback when it announced that two doses of the vaccine, which are one-tenth the amount of an adult dose, did not produce a sufficient immune response in children aged 2 to 4. The company has already started testing a third dose for this age group.

“As hospitalizations of children under 5 due to COVID-19 have soared, our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus,” Pfizer Chairman and CEO Albert Bourla, said in a company statement announcing the move.

“Ultimately, we believe that three doses of the vaccine will be needed for children 6 months through 4 years of age to achieve high levels of protection against current and potential future variants," Bourla added. "If two doses are authorized, parents will have the opportunity to begin a COVID-19 vaccination series for their children while awaiting potential authorization of a third dose.”

It is a strategy federal regulators have encouraged as they have been eager to review Pfizer's data in hopes of authorizing shots for young children as early as the end of February, multiple people familiar with the discussions told the Washington Post. If Pfizer waits for data on three doses, the request would not be submitted until late March.

“We know that two doses isn’t enough, and we get that,” one of the people familiar with the situation told the Post. “The idea is, let’s go ahead and start the review of two doses. If the data holds up in the submission, you could start kids on their primary baseline months earlier than if you don’t do anything until the third-dose data comes in.”

Last Friday, Pfizer briefed federal health officials on updated trial data on the shots, an administration official who spoke on the condition of anonymity, told the Post.

Those attending the briefing included Dr. Anthony Fauci; David Kessler, chief science officer for the government's COVID-19 response; a representative from the U.S. Centers for Disease Control and Prevention; and other officials from the U.S. Department of Health and Human Services, the Post reported.

The session included a “robust conversation” that three doses were likely to be much more powerful than just two shots, the administration official said. “But to get to three, you have to get two shots first. … There’s interest in seeing this move forward,” the official told the Post.

In that vein, an FDA advisory panel will weigh the two-dose regime on Feb. 15.

But at least one panel member voiced concerns about the highly unusual "rolling authorization."

Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, suggested that regulators could be short-circuiting the normal process without a clear rationale.

“It doesn’t make sense we would approve a two-dose vaccine on the assumption the third dose would make up for deficiencies of the two doses,” he told The New York Times.

The deficiencies were significant: One person familiar with the data, who spoke on condition of anonymity, told the Times that children aged 2 to 4 who were given two shots were infected at a rate 57 percent lower than the children who were not, and those between the ages of 6 months to 2 years old who got shots were infected at a rate 50 percent lower than those who were not. There were fewer than 100 cases of symptomatic infection — a small fraction of the participants overall — and the margins of error were wide, the person noted.

FDA panel member Dr. H. Cody Meissner, chief of the pediatric infectious diseases division at Tufts Children’s Hospital in Boston, said he was willing to weigh the "rolling authorization" strategy but he worried that rare side effects might be missed in the small-scale trials conducted so far.

The panel’s decision “will partly depend on what are the rates of hospitalization and severe disease in this age group, and what our sense is in terms of potential harm” should the two-dose regimen be authorized, Meissner added.

But Acting FDA Commissioner Dr. Janet Woodcock and Dr. Peter Marks, who oversees the agency's vaccines office, said Tuesday that it was important to act quickly given the surge in Omicron cases and the likelihood that other variants will follow.

“The need for a safe and effective vaccine for our youngest children is significant, particularly given the rapid spread of the Omicron variant, the notable rise in the number of hospitalizations in young children with severe disease and the possibility that future variants could cause severe disease in those who are unvaccinated,” Marks said in an agency statement.

As the Omicron variant has spread, there has been a steep increase in pediatric cases of the virus, according to the American Academy of Pediatrics (AAP), which gathers state-level data. Even though most young children tend to do well combating the virus, some can get very ill.

AAP President Dr. Moira Szilagyi said in a statement on Tuesday that she was encouraged that “we may be one step closer” to shots for the youngest children.

Last month, “we reported the highest number of COVID-19 cases among children since the pandemic’s onset. More than 3.5 million new cases in children were reported in January 2022 alone,” she told the Times.

If the two-dose regimen is authorized, not every parent is going to race to their pediatricians office for shots, according to a new survey from the Kaiser Family Foundation: Only 3 in 10 parents of children under 5 said they plan to get their children vaccinated as soon as shots become available.

More information

Visit the U.S. Food and Drug Administration for more on COVID vaccines.


SOURCE: Pfizer, news release, Feb. 1, 2022; U.S. Food and Drug Administration, news release, Feb. 1, 2022; The New York Times; Washington Post